Contact us and hear more of our unique ExpreS2 system for #protein proces development and mfg of #antigens #vaccines

ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial - read the news here:

Big 2024 milestones for @ExpreS2ionB:.🚀 CTA approved for Phase I clinical trial.🔬 Progress in preclinical vaccine programs.🤝 Term sheet with @SerumInstIndia .Watch the CEO interview 🎥.Exciting 2025 ahead! 🌟 #VaccinesWork #Biotech #Innovation.

RT @UniofOxford: NEW: The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and….

Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine ..#malaria #malariaresearch #ClinicalTrials #ExpreS2 @UniofOxford.

ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer - #breastcancerresearch #breastcancer #vaccinessavelives

ExpreS2ion to present in upcoming investor and scientific events via @cision.

ExpreS2ion Biotech will present at the BioStock Life Science Summit, November 21 via @cision.

ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002 . #cmv #vaccineswork #vaccinessavelives #ExpreS2 #biotech.

📢Listen to a brief Q&A video revolving the recently announced term sheet between @ExpreS2ionB and @SerumInstIndia , as well the newly resolved Reverse Split #VaccinesWork #VaccinesSaveLices #malaria #reversesplit

ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines.#malariaresearch #malariaclinicalvaccine #vaccinessavelives.

Brief interview with CEO Bent Frandsen at last week's @BioStock_SWE Stockholm event "Investing in Life Science from Seed to Success" - check it out: .#vaccineswork #vaccinessavelives #breastcancer #breastcancerresearch.

ExpreS2ion submits Clinical Trial Application (CTA) to conduct Phase I study of ES2B-C001, an innovative therapeutic breast cancer vaccine

ExpreS2ion announces final outcome of its rights issue via @cision.

ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting via @cision #drosophila #ExpreS2 #glyco #biotech #vaccines #vaccineswork.

Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine via @cision #vaccineswork #Vaccinessavelives #malaria #malariavaccineresearch.

Rights issue takes Expres2ion breast cancer vaccine to phase I via @BioStock_SWE #vaccineswork #vaccinessavelives #breastcancer #breastcancerresearch.

ExpreS2ion CEO: “Compelling preclinical package gives us confidence” via @BioStock_SWE #vaccineswork #vaccinessavelives #breastcancer #breastcancerresearch.

@ExpreS2ionB is thrilled to present at the first ever BioStock Global Forum, taking place in Lund on May 29-30. Apply for a spot and let's meet there, at Globalforum2024 - @BioStock_SWE ..#GlobalForum2024 #VaccinesWork

🌍 #WorldMalariaDay2024 - April 25 🦟.Today, we stand united in the fight against malaria. Proud to play a role in malaria vaccine projects at the University of Oxford, based on antigens made in our proprietary ExpreS2 production platform. 🧬💉 #EndMalaria #MalariaVaccine

ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS.